{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:28:49Z","timestamp":1791822529125,"version":"4.3.4"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1307601"],"award-info":[{"award-number":["2024YFA1307601"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1307602"],"award-info":[{"award-number":["2024YFA1307602"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1307603"],"award-info":[{"award-number":["2024YFA1307603"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drup.2026.101378","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:22:29Z","timestamp":1771028549000},"page":"101378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array\u2013based cytokine profiling"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-8026","authenticated-orcid":false,"given":"Rochelle","family":"Wickramasekara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4204-9959","authenticated-orcid":false,"given":"Valerie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guogui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Pan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101378_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101378_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10637-023-01410-2","article-title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","volume":"42","author":"Armstrong","year":"2024","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.drup.2026.101378_bib3","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.22.01994","article-title":"Randomized phase II Trial of Ficlatuzumab With or Without Cetuximab in pan-refractory, recurrent\/metastatic head and neck cancer","volume":"41","author":"Bauman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase i trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib5","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1158\/1078-0432.CCR-20-1696","article-title":"Pediatric PK\/PD Phase I trial of pexidartinib in relapsed and refractory leukemias and solid tumors including neurofibromatosis type i-related plexiform neurofibromas","volume":"26","author":"Boal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101378_bib6","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","article-title":"Motixafortide and Pembrolizumab Combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT\/KEYNOTE-202 Trial","volume":"27","author":"Bockorny","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101378_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040991","article-title":"Oncogenic linear collagen vi of invasive breast cancer is induced by ccl5","volume":"9","author":"Brett","year":"2020","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.drup.2026.101378_bib8","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0808-2","article-title":"Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance","volume":"9","author":"Che","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101378_bib10","article-title":"Lnc-H19-derived protein shapes the immunosuppressive microenvironment of glioblastoma","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.drup.2026.101378_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.canlet.2021.01.017","article-title":"LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation","volume":"503","author":"Chen","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101378_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-020-0272-5","article-title":"Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells","volume":"6","author":"Cheteh","year":"2020","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.drup.2026.101378_bib13","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101378_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","article-title":"Macrophage Regulation of Tumor Responses to Anticancer Therapies","volume":"23","author":"De Palma","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101378_bib15","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib16","first-page":"258","article-title":"Protein- And growth-modulatory effects of carcinoma-associated fibroblasts on breast cancer cells: Role of interleukin-6","volume":"56","author":"Dittmer","year":"2020","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib17","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1073\/pnas.1820459116","article-title":"Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma","volume":"116","author":"Ebbing","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101378_bib18","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1158\/2159-8290.CD-23-0601","article-title":"p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression","volume":"13","author":"Efe","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101378_bib19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101378_bib20","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101378_bib21","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/s42003-024-07144-y","article-title":"ZBTB18 regulates cytokine expression and affects microglia\/macrophage recruitment and commitment in glioblastoma","volume":"7","author":"Ferrarese","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.drup.2026.101378_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.drup.2026.101378_bib23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/carcin\/bgs123","article-title":"Tumor-associated neutrophils: friend or foe?","volume":"33","author":"Fridlender","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.drup.2026.101378_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101378_bib25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drup.2026.101378_bib26","doi-asserted-by":"crossref","first-page":"e2062","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101378_bib27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non\u2013Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial","volume":"42","author":"Garon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib28","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41571-025-01059-1","article-title":"Understanding and overcoming multidrug resistance in cancer","volume":"22","author":"Ge","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade","volume":"10","author":"Gomez-Roca","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007847","article-title":"High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy","volume":"11","author":"Han","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101378_bib32","article-title":"Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma","volume":"15","author":"He","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101378_bib33","doi-asserted-by":"crossref","unstructured":"Heenatigala Palliyage G., Samart P., Bobbala S., Rojanasakul L.W., Coyle J., Martin K., et al. Chemotherapy-induced PDL-1 expression in cancer-associated fibroblasts promotes chemoresistance in NSCLC. 2023.","DOI":"10.1016\/j.lungcan.2023.107258"},{"key":"10.1016\/j.drup.2026.101378_bib34","article-title":"Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis","volume":"3","author":"Hendrikson","year":"2022","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.drup.2026.101378_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000326","article-title":"Simultaneous inhibition of CXCR1\/2, TGF-\u03b2, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity","volume":"8","author":"Horn","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib36","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","article-title":"Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms","volume":"39","author":"Hu","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101378_bib37","doi-asserted-by":"crossref","unstructured":"Iuliani M., Simonetti S., Pantano F., Ribelli G., Martino A.Di, Denaro V., et al. Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma. Biology (Basel) 2021;10:781. https:\/\/doi.org\/10.3390\/biology.","DOI":"10.3390\/biology10080781"},{"key":"10.1016\/j.drup.2026.101378_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbcan.2016.03.005","article-title":"Cytokines in cancer drug resistance: Cues to new therapeutic strategies","volume":"1865","author":"Jones","year":"2016","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1152\/physrev.00046.2024","article-title":"Angiocrine and pericrine signaling: how endothelial cells and pericytes drive cancer progression and therapy resistance","volume":"106","author":"Jordan","year":"2026","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.drup.2026.101378_bib41","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib42","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1158\/0008-5472.CAN-17-2268","article-title":"IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment","volume":"78","author":"Karakasheva","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101378_bib43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature06188","article-title":"Mesenchymal stem cells within tumour stroma promote breast cancer metastasis","volume":"449","author":"Karnoub","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101378_bib44","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-20-1803","article-title":"Multicenter phase I\/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503\/SCOOP Trial)","volume":"26","author":"Kawazoe","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101378_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.drup.2026.101378_bib46","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101378_bib47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrd2006","article-title":"Multiplexed protein measurement: technologies and applications of protein and antibody arrays","volume":"5","author":"Kingsmore","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2026.101378_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/stem.559","article-title":"Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?","volume":"29","author":"Klopp","year":"2011","journal-title":"Stem Cells"},{"key":"10.1016\/j.drup.2026.101378_bib49","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.drup.2026.101378_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101378_bib51","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190290","article-title":"Emerging roles of IL-34 in health and disease","volume":"217","author":"Lelios","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2026.101378_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082968","article-title":"Overcoming intrinsic doxorubicin resistance in melanoma by anti-angiogenic and anti-metastatic effects of liposomal prednisolone phosphate on tumor microenvironment","volume":"21","author":"Licarete","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101378_bib53","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5684","article-title":"Drug resistance and tumor immune microenvironment: An overview of current understandings (Review)","volume":"65","author":"Liu","year":"2024","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","article-title":"Targeting TGF\u03b2 signal transduction for cancer therapy","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.drup.2026.101378_bib55","first-page":"144","article-title":"CXCR4 Antagonist AMD3100 (Plerixafor) Modulates Immune Responses in the Tumor Microenvironment","volume":"8","author":"Liu","year":"2021","journal-title":"Int J. Cancer Clin. Res"},{"key":"10.1016\/j.drup.2026.101378_bib56","article-title":"Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer","volume":"14","author":"Lu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101378_bib57","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.trecan.2020.02.020","article-title":"Tumour Cell Secretome in Chemoresistance and Tumour Recurrence","volume":"6","author":"Madden","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib59","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101378_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin Immunol."},{"key":"10.1016\/j.drup.2026.101378_bib61","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jtho.2016.05.038","article-title":"A randomized phase 2 study comparing the combination of ficlatuzumab and gefitinib with gefitinib alone in asian patients with advanced stage pulmonary adenocarcinoma","volume":"11","author":"Mok","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib62","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4049\/jimmunol.172.2.834","article-title":"TGF-\u03b21 Plays an Important Role in the Mechanism of CD4+CD25+ Regulatory T Cell Activity in Both Humans and Mice","volume":"172","author":"Nakamura","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2026.101378_bib63","article-title":"Interrogating glioma-M2 macrophage interactions identifies Gal-9\/Tim-3 as a viable target against PTEN-null glioblastoma","volume":"8","author":"Ni","year":"2022"},{"key":"10.1016\/j.drup.2026.101378_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.637675","article-title":"The role of tumor-stroma interactions in drug resistance within tumor microenvironment","volume":"9","author":"Ni","year":"2021","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.drup.2026.101378_bib65","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1158\/1078-0432.CCR-18-3684","article-title":"Loss of Smad4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via the CXCL1\/8\u2013CXCR2 axis","volume":"25","author":"Ogawa","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101378_bib66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival","volume":"25","author":"\u00d6zdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101378_bib67","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non\u2013Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101378_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107451","volume":"189","author":"Paz-Ares","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib69","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-\u03b2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib70","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","article-title":"The extracellular matrix modulates the hallmarks of cancer","volume":"15","author":"Pickup","year":"2014","journal-title":"EMBO Rep."},{"key":"10.1016\/j.drup.2026.101378_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1343523","article-title":"Dynamic interactions in the tumor niche: how the cross-talk between CAFs and the tumor microenvironment impacts resistance to therapy","volume":"11","author":"Piwocka","year":"2024","journal-title":"Front Mol. Biosci."},{"key":"10.1016\/j.drup.2026.101378_bib72","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-15-0876","article-title":"Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing","volume":"75","author":"Placencio","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101378_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8081158","article-title":"Role of MYC-miR-29-B7-H3 in medulloblastoma growth and angiogenesis","volume":"8","author":"Purvis","year":"2019","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.drup.2026.101378_bib74","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2026.101378_bib75","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2026.101378_bib76","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1158\/0008-5472.CAN-18-3800","article-title":"IL12 abrogates calcineurin-dependent immune evasion during leukemia progression","volume":"79","author":"Rabe","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101378_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46835-2","article-title":"Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma","volume":"15","author":"Ramirez","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101378_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.789885","article-title":"Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms","volume":"11","author":"Ribelli","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-017-0597-8","article-title":"Mesenchymal stem cells: key players in cancer progression","volume":"16","author":"Ridge","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib80","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drup.2026.101378_bib81","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-2149-1","article-title":"Cancer-educated mesenchymal stem cells promote the survival of cancer cells at primary and distant metastatic sites via the expansion of bone marrow-derived-PMN-MDSCs","volume":"10","author":"Sai","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101378_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119975","article-title":"The role of tumor-stroma interactions on desmoplasia and tumorigenicity within a microengineered 3D platform","volume":"247","author":"Saini","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.drup.2026.101378_bib84","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T Cells and Immune Tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101378_bib85","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101378_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-022-03675-4","article-title":"Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma","volume":"5","author":"Shi","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.drup.2026.101378_bib87","article-title":"Cancer statistics, 2025","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101378_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004992","article-title":"Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression","volume":"4","author":"Spaeth","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2026.101378_bib89","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung","volume":"35","author":"Spigel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib90","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1086862","article-title":"Tumor-intrinsic oncogene pathways mediating immune avoidance","volume":"5","author":"Spranger","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drup.2026.101378_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030381","article-title":"Targeting the gp130\/STAT3 Axis Attenuates Tumor Microenvironment Mediated Chemoresistance in Group 3 Medulloblastoma Cells","volume":"11","author":"Sreenivasan","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drup.2026.101378_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03241-y","article-title":"Autocrine IL-6\/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma","volume":"11","author":"Sreenivasan","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101378_bib93","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101378_bib94","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41576-019-0093-7","article-title":"Integrative single-cell analysis","volume":"20","author":"Stuart","year":"2019","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.drup.2026.101378_bib95","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","article-title":"CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101378_bib96","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.23.00980","article-title":"Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non\u2013Small-Cell Lung Cancer: Results From the CANOPY-1 Trial","volume":"42","author":"Tan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib97","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/eji.201847659","article-title":"Targeting Treg cells in cancer immunotherapy","volume":"49","author":"Tanaka","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.drup.2026.101378_bib98","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","article-title":"Ferroptosis, necroptosis, and pyroptosis in anticancer immunity","volume":"13","author":"Tang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib99","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/pmic.200300600","article-title":"Protein microarrays: Promising tools for proteomic research","volume":"3","author":"Templin","year":"2003","journal-title":"Proteomics"},{"key":"10.1016\/j.drup.2026.101378_bib100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/0008-5472.CAN-17-0524","article-title":"Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation","volume":"78","author":"Tommelein","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101378_bib101","first-page":"2912","article-title":"Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling","volume":"8","author":"Tuxhorn","year":"2002","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101378_bib102","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101378_bib103","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101378_bib104","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.drup.2026.101378_bib105","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijrobp.2022.12.029","article-title":"Cancer-Associated Fibroblasts Promote Radioresistance of Breast Cancer Cells via the HGF\/c-Met Signaling Pathway","volume":"116","author":"Wang","year":"2023","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.drup.2026.101378_bib106","article-title":"ENO1 Binds to ApoC3 and Impairs the Proliferation of T Cells via IL-8\/STAT3 Pathway in OSCC","volume":"23","author":"Wang","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.drup.2026.101378_bib107","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.drup.2026.101378_bib108","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2021.12.016","article-title":"Hippo\/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ\/IL-34 axis","volume":"527","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101378_bib109","first-page":"1","article-title":"Unraveling Immunotherapy Resistance in Solid Tumors: Decoding Mechanisms and Charting Future Therapeutic Landscapes","volume":"0","author":"Wang","year":"2025","journal-title":"Oncol. Res"},{"key":"10.1016\/j.drup.2026.101378_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010088","article-title":"A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype","volume":"5","author":"Waterman","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2026.101378_bib111","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib112","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12014-024-09452-1","article-title":"Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers","volume":"21","author":"Wenk","year":"2024","journal-title":"Clin. Proteom."},{"key":"10.1016\/j.drup.2026.101378_bib113","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/omi.2006.10.411","article-title":"Antibody microarrays: current status and key technological advances","volume":"10","author":"Wingren","year":"2006","journal-title":"OMICS"},{"key":"10.1016\/j.drup.2026.101378_bib114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-59745-372-1_5","article-title":"Antibody-based microarrays","volume":"509","author":"Wingren","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drup.2026.101378_bib115","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101275","article-title":"Hypoxia-induced upregulation of HIF1A-AS3 promotes MSC transition to cancer-associated fibroblasts and confers drug resistance in gastric cancer","volume":"82","author":"Xu","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2026.101378_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113270","article-title":"Collagen 1-mediated CXCL1 secretion in tumor cells activates fibroblasts to promote radioresistance of esophageal cancer","volume":"42","author":"Yang","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.drup.2026.101378_bib118","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101378_bib119","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1158\/2326-6066.CIR-20-0312","article-title":"Targeted deletion of CXCR2 in myeloid cells alters the tumor immune environment to improve antitumor immunity","volume":"9","author":"Yang","year":"2021","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.drup.2026.101378_bib120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.drup.2026.101378_bib121","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.drup.2026.101378_bib122","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13402-019-00446-y","article-title":"Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells","volume":"42","author":"Yin","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib123","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.7150\/jca.37932","article-title":"Mesenchymal stem\/stromal cells-derived IL-6 promotes nasopharyngeal carcinoma growth and resistance to cisplatin via upregulating CD73 expression","volume":"11","author":"Zeng","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.drup.2026.101378_bib124","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41388-022-02540-2","article-title":"CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype","volume":"42","author":"Zeng","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101378_bib125","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.7150\/ijbs.72534","article-title":"Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance","volume":"18","author":"Zhang","year":"2022","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.drup.2026.101378_bib126","article-title":"ZNF451 favors triple-negative breast cancer progression by enhancing SLUG-mediated CCL5 transcriptional expression","volume":"42","author":"Zhang","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.drup.2026.101378_bib127","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1097\/JS9.0000000000002611","article-title":"Prostate cancer stem cell dynamics in the evolution of drug resistance","volume":"111","author":"Zhang","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.drup.2026.101378_bib128","doi-asserted-by":"crossref","DOI":"10.5582\/ddt.2025.01058","article-title":"Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)","author":"Zhao","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.drup.2026.101378_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16203459","article-title":"CCL21 Induces Plasmacytoid Dendritic Cell Migration and Activation in a Mouse Model of Glioblastoma","volume":"16","author":"Zhao","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101378_bib130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41401-022-00927-1","article-title":"Calcipotriol abrogates cancer-associated fibroblast-derived IL-8-mediated oxaliplatin resistance in gastric cancer cells via blocking PI3K\/Akt signaling","volume":"44","author":"Zhao","year":"2023","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.drup.2026.101378_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.584505","article-title":"Endothelial cells promote docetaxel resistance of prostate cancer cells by inducing ERG expression and activating Akt\/mTOR signaling pathway","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.drup.2026.101378_bib132","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02224-x","article-title":"Targeting ZFP64\/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer","volume":"41","author":"Zhu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:27:05Z","timestamp":1781825225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":132,"alternative-id":["S1368764626000294"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101378","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of therapy resistance in the tumor microenvironment: Insights from antibody array\u2013based cytokine profiling","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101378"}}